Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845645 | 1.00 | TDP1 (0.47) | TDP1USP2CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL669311 | 1.00 | TDP1 (0.47) | TDP1USP2CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL28554669 | 1.00 | TDP1 (0.47) | TDP1USP2CYP3A4MAPTSMN1; SMN2 | |
| Bromide SCHEMBL1290055 | 0.98 | TDP1 (0.46) | TDP1USP2CYP3A4MAPTSMN1; SMN2 | |
| Bromide SCHEMBL1290128 | 0.98 | TDP1 (0.46) | TDP1USP2CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL9679260 | 0.95 | TDP1 (0.49) | TDP1USP2CYP3A4MAPTSMN1; SMN2 | |
| Propanol SCHEMBL4985613 | 0.93 | TDP1 (0.41) | TDP1 | |
| SCHEMBL6234229 | 0.89 | TDP1 (0.46) | TDP1USP2CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL17276716 | 0.86 | TSHR (0.44) | TDP1CYP3A4ALDH1A1HPGD | |
| SCHEMBL9737328 | 0.85 | TDP1 (0.46) | TDP1USP2CYP3A4MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425809-A | Preparation method of fluorosugar | 复旦大学 | 2023-07-14 | — | — | CN | disclosed |
| US-10174065-B2 | Antidiabetic enolic glucoside of phenylpyruvic acid | ZADEC APS (DK) | 2019-01-08 | — | — | US | disclosed |
| US-20160083411-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | ZADEC APS (DK) | 2016-03-24 | — | — | US | disclosed |
| US-9221860-B2 | Antidiabetic enolic glucoside of phenylpyruvic acid | ZADEC APS (DK) | 2015-12-29 | — | — | US | disclosed |
| EP-2625184-B1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | ZADEC APS (DK) | 2014-10-01 | — | — | EP | disclosed |
| US-20130310331-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | ZADEC APS (DK) | 2013-11-21 | — | — | US | disclosed |
| US-20100069607-A1 | METHOD OF COVALENTLY LINKING A CARBOHYDRATE OR POLYALKYLENE OXIDE TO A PEPTIDE, PRECURSORS FOR USE IN THE METHOD AND RESULTANT PRODUCTS | UCL BUSINESS PLC (GB) | 2010-03-18 | — | — | US | disclosed |
| EP-0751144-B1 | Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy | PHARMACHEMIE BV (NL) | 2004-10-06 | — | — | EP | disclosed |
| US-20040096951-A1 | Crystal structures of retaining glycosytransferases | BRITISH COLUMBIA, UNIVERSITY OF , THE (CA) | 2004-05-20 | — | — | US | disclosed |
| WO-2002048320-A2 | CRYSTAL STRUCTURES OF RETAINING GLYCOSYLTRANSFERASES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2002-06-20 | — | — | WO | disclosed |
| EP-0751144-A1 | Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy | PHARMACHEMIE B.V. (NL) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174065-B2 | Antidiabetic enolic glucoside of phenylpyruvic acid | PC, SLC5A1, SLC5A2 | TDP1 3786/4885USP2 4377/4885CYP3A4 467/4885 |
| US-20160083411-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | PC, SLC5A1, SLC5A2 | TDP1 3786/4885USP2 4377/4885CYP3A4 467/4885 |
| US-20100069607-A1 | METHOD OF COVALENTLY LINKING A CARBOHYDRATE OR POLYALKYLENE OXIDE TO A PEPTIDE, PRECURSORS FOR USE IN THE METHOD AND RESULTANT PRODUCTS | MSR1, C9, ADM2 | TDP1 4445/4885USP2 1489/4885CYP3A4 3369/4885 |
| US-20130310331-A1 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID | PC, SLC5A1, SLC5A2 | TDP1 3786/4885USP2 4377/4885CYP3A4 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.